PTC
CPRX

Private Trust Company’s Catalyst Pharmaceutical CPRX Stock Holding History

Private Trust Company’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-396
Closed -$9.8K – 2724
2026
Q1 		$9.8K Hold
396
– – ﹤0.01% 1984
2025
Q4 		$9.24K Buy
+396
New +$8.82K ﹤0.01% 1962

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Private Trust Company's CPRX Position: Q2 2026 in Review

Private Trust Company sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 396 shares — an estimated $9.8K sold.

Private Trust Company first reported a position in CPRX in Q4 2025 and held it in 2 quarters. The position peaked at $9.8K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Private Trust Company reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Private Trust Company sold 396 Catalyst Pharmaceutical shares in Q2 2026, an estimated $9.8K.
  • Private Trust Company first reported a position in Catalyst Pharmaceutical in Q4 2025 and held it in 2 quarters.
  • Private Trust Company's Catalyst Pharmaceutical position peaked at $9.8K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.